Mobile website
Archive > Volume 31 Issue 8 > 2024,31(8):752-758. DOI:10.3872/j.issn.1007-385X.2024.08.002 Prev Next
Standard and Guideline
Expert consensus on clinical application of Drug-Loaded Microparticles Immunotherapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
With the rapid development of precision medicine, extracellular vesicles (EVs) have shown tremendous potential in the diagnosis and therapeutic applications of diseases such as tumors. Drug-Loaded Microparticles Immunotherapy is an innovative cancer immunotherapy technology originating in China. It utilizes tumor-derived microparticles as carriers, encapsulating or loading commonly used clinical small molecule chemotherapeutic drugs. This approach achieves effective tumor destruction through mechanisms such as targeted drug delivery, activation of neutrophils, reversal of macrophages polarization, and enhancement of tumor antigen presentation. Over more than a decade of research into anti-tumor mechanisms, preclinical assessments, and clinical trials, this technology has successfully transitioned to clinical application and received clinical approval. To further advance the standardized and scientific application of Drug-Loaded Microparticles Immunotherapy, Committee for Tumor Immunology & Biotherapy of Chinese Society for Immunology and the Society of Cancer Biotherapy of China Anti-Cancer Association jointly organized technical and clinical experts in the fields of extracellular vesicles and tumor immunotherapy. After multiple rounds of discussions and revisions, they collaboratively drafted the“ Expert Consensus on Clinical Application of Drug-Loaded Microparticles Immunotherapy”. This consensus introduces the research and practical application of the therapy in cancer treatment, addresses existing challenges, and outlines future development directions. Its primary goal is to offer guidance and insights for the optimal clinical use of this innovative therapeutic approach.
Keywords:
Project Supported:
Clc Number:
